Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)

16.10
Delayed Data
As of Sep 27
 +0.59 / +3.80%
Today’s Change
7.35
Today|||52-Week Range
16.11
+38.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$2.3B

Company Description

Ironwood Pharmaceuticals, Inc. is an pharmaceutical company. It discovers, develops and intends to commercialize differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.

Contact Information

Ironwood Pharmaceuticals, Inc.
301 Binney Street
Cambridge Massachusetts 02142
P:(617) 621-7722
Investor Relations:
(617) 768-2628

Employees

Shareholders

Individual stakeholders8.52%
Mutual fund holders62.49%
Other institutional45.15%

Top Executives

Peter M. HechtChief Executive Officer & Director
Thomas GraneyChief Financial Officer & SVP-Corporate Strategy
Brian M. CaliSenior VP-Preclinical, Research & Development
Mark G. CurrieChief Scientific Officer & Senior Vice President
Michael L. HallSenior Vice President-Clinical Development